obesity drug news today glp-1 today The current range of weight-loss drugs on the market targets receptors. Seeking a new generation of weight-loss drugs, some companies are developing amylin analogs. Read more: https://brnw.ch/21x1oec Are you eligible? Medicare's new
Description
Data verification and validation: A.S.K., S.W.B., A.R.S., D.W.P., M.C.G., J.B.K., D.R.D., P.M.L., C.B., J.-P.F., D.A.T., and M.S.L
7 As the benefits of the GLP-1 receptor agonists with T2D, obesity, and cardiovascular health are becoming widely known, research into using these agents to treat other conditions has accelerated
[8] demonstrated that the incretin effect is impaired in patients with T2D
This marked a significant step forward in diabetes treatment
Note that the BALANCE demonstration applies to adults with a BMI of 35 or higher, so not all Medicare patients will qualify
Its not FDA-approved for obesity
